Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics

DelveInsight's "Glioma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Glioma Market with DelveInsight's In-Depth Report @ Glioma Market Size- https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Glioma Market Report
• In February 2025:- Eli Lilly and Company:- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
• In February 2025:- Chimerix:- This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
• In February 2025:- Day One Biopharmaceuticals, Inc.:- This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
• The Glioma market size was valued approximately USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• According to DelveInsight's projections, the United States represented roughly 40% of all glioma incident cases across the 7MM in 2023.
• In the United States, Grade IV glioma had the highest incidence, with approximately 13,200 cases, followed by Grade II glioma. Grade I glioma had the lowest number of cases among all grades.
• In 2023, the age group of 60-74 years had the highest incidence of glioma cases, constituting approximately 36% of the total cases, which is roughly 6,900 cases. This was followed by the age group of 45-59 years, which accounted for around 25% of the cases, totaling about 4,900 cases in the US.
• In 2023, the United States recorded the largest number of incident cases, constituting around 40% of the total cases, which amounted to approximately 19,100 cases.
• Key Glioma Companies such as Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC, and others
• Key Glioma Therapies such as Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others

Stay ahead in the Glioma Therapeutics Market with DelveInsight's Strategic Report @ Glioma Market Outlook- https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioma Epidemiology Segmentation in the 7MM
• Total Prevalence of Glioma
• Prevalent Cases of Glioma by severity
• Gender-specific Prevalence of Glioma
• Diagnosed Cases of Episodic and Chronic Glioma

Download the report to understand which factors are driving Glioma epidemiology trends @ Glioma Prevalence- https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioma market or expected to get launched during the study period. The analysis covers Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

Glioma Therapies and Key Companies
• Pembrolizumab: Memorial Sloan Kettering Cancer Center
• safusidenib: AnHeart Therapeutics Inc.
• Abemaciclib: Eli Lilly and Company
• ONC201: Chimerix
• Rhenium Liposome Treatment: Plus Therapeutics
• ONC201: Chimerix
• PVSRIPO: Istari Oncology, Inc.
• Temodal: Armando Santoro, MD
• ERC1671: Epitopoietic Research Corporation
• APG-157: Aveta Biomics, Inc.
• ONC201: Chimerix
• Tovorafenib: Day One Biopharmaceuticals
• Pemigatinib: Incyte Corporation
• NMS-03305293: Nerviano Medical Sciences
• DS-1001b: Daiichi Sankyo Co., Ltd.
• Cerebraca wafer: Everfront Biotech Co., Ltd.
• DB107-RRV: Ashish Shah
• OKN-007: Oblato, Inc.
• DAY101: Day One Biopharmaceuticals
• BMX-001: BioMimetix JV, LLC

Glioma Market Strengths
• Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for GBM.
• Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed.

Glioma Market Opportunities
• Better prognostic markers would allow physicians to diagnose and begin treatment of glioma at early onset, possibly preventing disease progression.
• Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumors versus metastases and CNS masses, and true progression versus pseudo progression

Scope of the Glioma Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Glioma Companies: Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC., and others
• Key Glioma Therapies: Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Glioma Unmet Needs, KOL's views, Analyst's views, Glioma Market Access and Reimbursement

To know more about Glioma companies working in the treatment market, visit @ Glioma Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Glioma Market Report Introduction
2. Executive Summary for Glioma
3. SWOT analysis of Glioma
4. Glioma Patient Share (%) Overview at a Glance
5. Glioma Market Overview at a Glance
6. Glioma Disease Background and Overview
7. Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glioma
9. Glioma Current Treatment and Medical Practices
10. Glioma Unmet Needs
11. Glioma Emerging Therapies
12. Glioma Market Outlook
13. Country-Wise Glioma Market Analysis (2020-2034)
14. Glioma Market Access and Reimbursement of Therapies
15. Glioma Market Drivers
16. Glioma Market Barriers
17. Glioma Appendix
18. Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.